NOVEL ORAL COMBINATION CHEMOTHERAPY (CT) IN THE MANAGEMENT OF AIDS-RELATED NON-HODGKIN LYMPHOMA (NHL): LONGER FOLLOW-UP (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

NOVEL ORAL COMBINATION CHEMOTHERAPY (CT) IN THE MANAGEMENT OF AIDS-RELATED NON-HODGKIN LYMPHOMA (NHL): LONGER FOLLOW-UP (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 11:A20 1992. Unique Identifier : AIDSLINE ICDB/92680751
Remick S; McSharry J; Wolf B; Blanchard C; Powell D; Portuese E; Chikkappa G; Chaffee B; Pearse T; Wagner H; et al; Albany Medical Coll., Albany, NY 12208

Abstract: We previously reported (Proc ASCO 10:32, 1991) our initial experience with an oral-based combination CT regimen of CCNU 100 mg/m2 day (d) 1 (cycles 1, 3, 5), etoposide 20 mg/m2 d 1-3, cyclophosphamide and procarbazine 100 mg/m2 each d 22-31 administered to patients (pts) with AIDS-related NHL. Eighteen pts with good performance status and biopsy-proven NHL have been entered. In 13 pts NHL was the AIDS-defining illness and 13 had Stage III or IV disease. The regimen is myelosuppressive with 15 episodes of grade 3 and 7 episodes grade 4 neutropenia observed during the first 29 cycles of therapy, of which there were only 9 episodes of associated fever. There has been 1 toxic death. Overall objective response rate in the first 14 pts entered (4 pts too early) is 64% (CR 43% and PR 21%) with median survival of 7.5 mo (range 11 d to 22.5 mo). Flow cytometric detection of fluorescently labeled monoclonal antibody to p24 antigen of peripheral blood mononuclear cells (PBMC) has been studied in 9 pts to assess the impact of therapy on HIV antigenemia ( a pt is considered positive for p24 antigen when greater than or equal to 4% of PBMC are positive). Median percent p24 positive PBMC at time of on-study was 4.25% (range 1.07-12.69%) and 5.29% (range 1.88-22.0%) after a median interval of 5 mo (range 1-12 mo) of therapy. This regimen can be readily given to outpatients, is active, and except for myelosuppression is well tolerated.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS/PATHOLOGY Administration, Oral Antibodies, Monoclonal Antineoplastic Agents, Combined/*THERAPEUTIC USE Biopsy Cyclophosphamide/ADMINISTRATION & DOSAGE Etoposide/ADMINISTRATION & DOSAGE Flow Cytometry Follow-Up Studies Human HIV Core Protein p24/ANALYSIS Lomustine/ADMINISTRATION & DOSAGE Lymphoma, Non-Hodgkin's/*DRUG THERAPY/*ETIOLOGY/PATHOLOGY Procarbazine/ADMINISTRATION & DOSAGE Time Factors CLINICAL TRIAL ABSTRACT

921130
M92B0890

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .